Citigroup’s Onconetix ONCO Stock Holding History

Citigroup’s Portfolio ONCO Stock Details ONCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17	Closed	-$2.56K	–	6107
2026 Q1	$2.56K	Buy	+17	New	+$8.86K	﹤0.01%	5394
2022 Q2	–	Hold	0	–	-$135K	–	6535
2022 Q1	–	Hold	0	–	–	–	4279

Other funds holding ONCO

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Hollencrest Capital Management Newport Beach, California $1.56B AUM 20.98% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Citigroup's ONCO Position: Q2 2026 in Review

Citigroup sold out of Onconetix (ONCO) in Q2 2026, closing a stake of 17 shares — an estimated $2.56K sold.

Citigroup first reported a position in ONCO in Q1 2026 and held it in 1 quarter. The position peaked at $2.56K in Q1 2026. 6 funds tracked by Wall St. Rank hold ONCO as of Q2 2026.

Citigroup reported no remaining Onconetix position as of Q2 2026 after selling out during the quarter.
Citigroup sold 17 Onconetix shares in Q2 2026, an estimated $2.56K.
Citigroup first reported a position in Onconetix in Q1 2026 and held it in 1 quarter.
Citigroup's Onconetix position peaked at $2.56K in Q1 2026.
6 funds tracked by Wall St. Rank held Onconetix as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.